

MARKET REPORT



Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcylla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023.

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyła), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023.

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyła), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023.

The antibody drug conjugates market was valued at \$1,387 million in 2016, and is estimated to reach \$3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023. Antibody drug conjugates (ADC's) are promising and effective anticancer medications employed for efficient treatment of cancer patients. ADC's are biopharmaceutical drugs prepared by integrating two clinical approaches viz cell killing HPAPI (powerful pharmaceutical ingredient) and monoclonal antibody specificity. This combination approach enables elimination of cancer infected cells without harming healthy cells in patient's body.

Increase in global prevalence of cancer and demand for quality & cost-effective cancer medications drives the global ADCs market. In addition, extensive R&D for cancer medication and approval of new cancer drugs is expected to boost the market growth during the forecast period. However, high cost involved in R&D of cancer medication and stringent government regulations impedes the growth of antibody drug conjugates market.

The report segments the market based on drugs, mechanism of action, application, and region. Based on drugs, the market is bifurcated into Adcetris and Kadcyła. Based on mechanism of action, it is divided into CD30 antibodies and HER2 antibodies. Based on application, the market is classified into breast cancer, lymphoma, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2017 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.

Extensive analysis by product elucidates the various types of ADC's used for diverse cancer therapeutic procedures

Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.

Key players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global ADCs market.

KEY PLAYERS PROFILED

F. Hoffman-La Roche Ltd.

Novartis AG

Takeda Pharmaceutical Company Limited

Pfizer, Inc.

Seattle Genetics Inc.

Genentech Inc.

Immunogen Inc.

Immunomedics, Inc.

Progenics Pharmaceuticals Inc.

Bayer AG

KEY MARKET SEGMENTS

BY DRUGS

Adcetris

Kadcyla

BY MECHANISM OF ACTION

CD30 Antibodies

HER2 Antibodies

BY APPLICATION

Breast Cancer

Lymphoma

By Region

North America

U.S.

Canada

Mexico

Europe

France

Germany

UK

Italy
Spain
The Netherlands
Norway
Russia
Sweden
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
New Zealand
Taiwan
Thailand
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Chile
Columbia
Egypt
Iran
Israel
Turkey
Venezuela
Rest of LAMEA

The other players of the anesthesia market include (companies not profiled in the report):

Agensys, Inc.

Concortis Biotherapeutics

Sanofi S.A.

Celldex Therapeutics Inc.

Synthon Holding B.V.

Additional Details

Publisher : Allied Market Research

Reference : LI 171467

Number of Pages : 152

Report Format : PDF

Publisher Information :



Allied Market Research
Diligent Intelligence - Improved Growth

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023. [Report Updated: 01-09-2017]

- CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS1.3. KEY MARKET SEGMENTS1.4. RESEARCH METHODOLOGY1.4.1. Secondary research1.4.2. Primary research1.4.3. Analyst tools & modelsCHAPTER 2 EXECUTIVE SUMMARY2.1. CXO PERSPECTIVECHAPTER 3 MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top investment pockets3.2.2. Top winning strategies3.3. TOP PLAYER POSITIONING3.4. PATENTS ANALYSIS3.4.1. Patent analysis by year3.4.2. Patent analysis by region3.5. PORTERS FIVE FORCES ANALYSIS3.5. MARKET DYNAMICS3.5.1. Drivers3.5.2. Restraints3.5.3. OpportunitiesCHAPTER 4 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS4.1. OVERVIEW4.1.1. Market size & forecast4.2. ADCETRIS4.2.1. Key market trends4.2.2. Growth factors and opportunities4.2.3. Market size & forecast4.3. KADCYLA4.3.1. Key market trends4.3.2. Growth factors and opportunities4.3.3. Market size & forecastCHAPTER 5 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION5.1. OVERVIEW5.1.1. Market size & forecast5.2. CD30 ANTIBODIES5.2.1. Market size & forecast5.3. HER2 ANTIBODIES5.3.1. Market size & forecastCHAPTER 6 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION6.1. OVERVIEW6.1.1. Market size & forecast6.2. BREAST CANCER6.2.1. Market size & forecast6.3. LYMPHOMA6.3.1. Market size & forecastCHAPTER 7 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY7.1. OVERVIEW7.2. NORTH AMERICA7.2.1. Key market trends7.2.2. Key growth factors and opportunities7.2.3. Market size & forecast7.2.3.1. U.S. market size and forecast7.2.3.2. Canada market size and forecast7.2.3.3. Mexico market size and forecast7.3. EUROPE7.3.1. Key market trends7.3.2. Key growth factors and opportunities7.3.3. Market size & forecast7.3.3.1. Germany market size and forecast7.3.3.2. France market size and forecast7.3.3.3. UK market size and forecast7.3.3.4. Italy market size and forecast7.3.3.5. Spain market size and forecast7.3.3.6. Rest of Europe market size and forecast7.4. ASIA-PACIFIC7.4.1. Key market trends7.4.2. Key growth factors and opportunities7.4.3. Market size & forecast7.4.3.1. Japan market size and forecast7.4.3.2. China market size and forecast7.4.3.3. Australia market size and forecast7.4.3.4. India market size and forecast7.4.3.5. South Korea market size and forecast7.4.3.6. Taiwan market size and forecast7.4.3.7. Rest of Asia-Pacific market size and forecast7.5. LAMEA7.5.1. Key market trends7.5.2. Key growth factors and opportunities7.5.3. Market size & forecast7.5.3.1. Brazil market size and forecast7.5.3.2. Turkey market size and forecast7.5.3.3. Saudi Arabia market size and forecast7.5.3.4. South Africa market size and forecast7.5.3.5. Rest of LAMEA market size and forecastCHAPTER 8 COMPANY PROFILES8.1. PFIZER, INC.8.1.1. Operating business segments8.1.2. Business performance8.2. CELLDEX THERAPEUTICS INC.8.2.1. Operating business segments8.2.2. Business performance8.2.3. Key strategic moves and developments8.3. SEATTLE GENETICS INC.8.3.1. Operating business segments8.3.2. Business performance8.3.3. Key strategic moves and developments8.4. GENENTECH INC.8.4.1. Operating business segments8.4.2. Business performance8.4.3. Key strategic moves and developments8.5. IMMUNOGEN INC.8.5.1. Operating business segments8.5.2. Business performance8.5.3. Key strategic moves and developments8.5. SANOFI S.A.8.5.1. Operating business segments8.5.2. Business performance8.5.3. Key strategic moves and developments8.7. IMMUNOMEDICS, INC.8.7.1. Operating business segments8.7.2. Business performance8.7.3. Key strategic moves and developments8.8. PROGENICS PHARMACEUTICALS INC.8.8.1. Operating business segments8.8.2. Business performance8.8.3. Key strategic moves and developments8.8. BAYER HEALTHCARE PHARMACEUTICALS8.8.1. Operating business segments8.8.2. Business performance8.8.3. Key strategic moves and developments8.10. SYNTHON HOLDING B.V.8.10.1. Operating business segments8.10.2. Business performance8.10.3. Key strategic moves and developments

List Of Tables in Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023. [Report Updated: 01-09-2017]

TABLE 1. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 (\$MILLION)

TABLE 2. ADCETRIS ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 3. KADCYLA ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 (\$MILLION)

TABLE 5. CD30 ANTIBODIES ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 6. HER2 ANTIBODIES ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 8. BREAST CANCER ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 9. LYMPHOMA ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 10. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 11. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 (\$MILLION)

TABLE 12. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 (\$MILLION)

TABLE 13. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 (\$MILLION)

TABLE 14. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 15. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 (\$MILLION)

TABLE 16. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 (\$MILLION)

TABLE 17. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 (\$MILLION)

TABLE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 19. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 (\$MILLION)

TABLE 20. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 (\$MILLION)

TABLE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 (\$MILLION)

TABLE 22. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 23. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 (\$MILLION)

TABLE 24. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 (\$MILLION)

TABLE 25. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 (\$MILLION)

TABLE 26. PFIZER, INC.: COMPANY SNAPSHOT

TABLE 27. PFIZER, INC.: PRODUCT PORTFOLIO

TABLE 28. CELLDIX THERAPEUTICS INC: COMPANY SNAPSHOT

TABLE 29. CELLDIX THERAPEUTICS INC: PRODUCT PORTFOLIO

TABLE 30. SEATTLE GENETICS INC: COMPANY SNAPSHOT

TABLE 31. SEATTLE GENETICS INC: PRODUCT PORTFOLIO

TABLE 32. GENENTECH INC: COMPANY SNAPSHOT

TABLE 33. GENENTECH INC: PRODUCT PORTFOLIO

TABLE 34. IMMUNOGEN INC: COMPANY SNAPSHOT

TABLE 35. IMMUNOGEN INC: PRODUCT PORTFOLIO

TABLE 36. SANOFI S.A.: COMPANY SNAPSHOT

TABLE 37. SANOFI S.A.: PRODUCT PORTFOLIO

TABLE 38. IMMUNOMEDICS, INC: COMPANY SNAPSHOT

TABLE 39. IMMUNOMEDICS, INC: PRODUCT PORTFOLIO

TABLE 40. PROGENICS PHARMACEUTICALS INC.: COMPANY SNAPSHOT

TABLE 41. PROGENICS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO

TABLE 42. BAYER HEALTHCARE PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 43. BAYER HEALTHCARE PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 44. SYNTHON HOLDING B.V.: COMPANY SNAPSHOT

TABLE 45. SYNTHON HOLDING B.V.: PRODUCT PORTFOLIO

List Of Figures, Charts and Diagrams in Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcycla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023. [Report Updated: 01-09-2017]

FIGURE 1. ANTIBODY DRUG CONJUGATES MARKET: MARKET SEGMENTATION

FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL DNA SEQUENCING MARKET, BY APPLICATION

FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)

FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE

FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY

FIGURE 5. TOP PLAYER POSITIONING: GLOBAL ANTIBODY DRUG CONJUGATES MARKET

FIGURE 7. PATENT ANALYSIS BY YEAR

FIGURE 8. PATENT ANALYSIS BY REGION

FIGURE 9. BARGAINING POWER OF BUYERS

FIGURE 10. BARGAINING POWER OF SUPPLIERS

FIGURE 11. THREAT OF NEW ENTRANTS

FIGURE 12. THREAT OF SUBSTITUTION

FIGURE 13. COMPETITIVE RIVALRY

FIGURE 14. ANTIBODY DRUG CONJUGATES MARKET: DRUGS SEGMENTATION

FIGURE 15. ANTIBODY DRUG CONJUGATES MARKET: MECHANISM OF ACTION SEGMENTATION

FIGURE 16. ANTIBODY DRUG CONJUGATES MARKET: BY APPLICATION SEGMENTATION

FIGURE 17. U.S. ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 18. CANADA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 19. MEXICO ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 20. GERMANY ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 21. FRANCE ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 22. UK ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 23. ITALY ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 24. SPAIN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 25. REST OF EUROPE ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 26. JAPAN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 27. CHINA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 28. AUSTRALIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 29. INDIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 30. SOUTH KOREA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 31. TAIWAN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 32. REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 33. BRAZIL ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 34. TURKEY ANTIBODY DRUG CONJUGATES MARKET, 2016-20223 (\$MILLION)

FIGURE 35. SAUDI ARABIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 36. SOUTH AFRICA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

FIGURE 37. REST OF LAMEA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 (\$MILLION)

How to Buy...

Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcylla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023. [Report Updated: 01-09-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/123319>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3440** | Single User Price
- \$5910** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.